We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
- Authors
Ravandi, F; Arana Yi, C; Cortes, J E; Levis, M; Faderl, S; Garcia-Manero, G; Jabbour, E; Konopleva, M; O'Brien, S; Estrov, Z; Borthakur, G; Thomas, D; Pierce, S; Brandt, M; Pratz, K; Luthra, R; Andreeff, M; Kantarjian, H
- Abstract
The article presents the long-term outcomes of a study on the diagnosis of acute myeloid leukemia in patients treated with sorafenib, cytarabine and idarubicin for initial therapy. The study involves survival curves using Kaplan-Meier method and long-rank test as well as Fisher's exact test. The patients involved had D835 gene mutation, antecedent hematologic disorder and unfavorable cytogenetics. It notes that 61 patients had response assessment while one patient died before the assessment.
- Subjects
ACUTE myeloid leukemia diagnosis; CYTARABINE; IDARUBICIN; KAPLAN-Meier estimator; GENES; BLOOD diseases; HUMAN cytogenetics
- Publication
Leukemia (08876924), 2014, Vol 28, Issue 7, p1543
- ISSN
0887-6924
- Publication type
Article
- DOI
10.1038/leu.2014.54